A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-group Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs ASP 4345 (Primary) ; Aripiprazole; Brexpiprazole; Lurasidone; Olanzapine; Paliperidone; Quetiapine; Risperidone; Ziprasidone
- Indications Schizophrenia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Astellas Pharma Global Development
- 31 Oct 2019 Status changed from active, no longer recruiting to completed.
- 25 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 18 Jul 2018 Status changed from not yet recruiting to recruiting.